Researchers have identified two ubiquitin-like proteins, NEDD8 and SUMO2, that play opposing roles in maintaining healthy skin. The discovery, published by Genetic Engineering News, could form the basis of new strategies for treating skin conditions and potentially slowing cancer.
NEDD8 and SUMO2 were found to function in opposition, balancing skin cell integrity and turnover. The exact mechanisms remain under investigation, but the proteins' contrasting effects suggest a finely tuned regulatory system critical for skin homeostasis.
The research is in early stages, with no clinical trials yet announced. The pathway may offer targets for topical or systemic therapies, though years of preclinical work lie ahead before any human testing.
The implications extend beyond dermatology. The team highlighted potential applications in cancer, as disrupted protein modification pathways are common in tumor growth. However, targeting ubiquitin-like proteins systemically carries risks of off-target effects.
Experts caution that translating these findings into treatments requires extensive validation. The study's focus on basic biology underscores the gap between lab discovery and clinical therapy, but the dual-protein mechanism provides a novel angle for drug development.